Download Cubist Pharmaceuticals, Inc.

Cubist Pharmaceuticals, Inc.
Infectious Disease  CNS  Cardiovascular Disease
DELEGATE(S)
Brad Prosek
65 Hayden Avenue
Lexington, MA 02421
USA
HIGHLIGHTS
Recent
www.cubist.com
Cubist Pharmaceuticals and Hydra Biosciences announce plans to begin Phase 1 Clinical
Trial for Novel TRPA1 Modulator to treat acute pain.
Incorporated: 1992
Employees:
700
Ownership:
Public
Cubist announces Full Year 2011 total CUBICIN® net product revenues of USD $735.5
Million, up 18% over 2010.
NASDAQ: CBST
Cubist announces first patient dosed in pivotal global Phase 3 Trial of CXA-201 for
Complicated Intra-Abdominal Infections.
MISSION/BACKGROUND
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of
pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in
Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.
ALLIANCES
Optimer, AstraZeneca, Novartis, Merck-Banyu, Hydra Biosciences, others...
PRODUCTS
Name
Phase
Indication
CUBICIN
On Market
Bacterial Infection
ENTEREG
On Market
Post Operative Ileus
DIFICID
On Market
Clostridium Difficile Infections
CXA-201
Phase III
Gram Negative Infections
CB 183, 315
Phase III
Clostridium Difficile Infections
Novel TRPA1 Modulator
Phase I
Acute Pain
Company Profiles – 10